Asset sale Announced

Royalty Pharma acquisition of PTC Therapeutics' remaining royalty on Roche's Evrysdi

US$240m consideration

Announced 6 Jan 2026

Advisers

PTC Therapeutics' remaining royalty on Roche's Evrysdi

Target

Not disclosed

Royalty Pharma

Acquirer

Target
PTC Therapeutics' remaining royalty on Roche's Evrysdi
Acquirer
Royalty Pharma
Seller
PTC Therapeutics
Buyer based in
United States
Seller based in
United States
Sector
Specialty finance and leasing
Tags
Specialty finance and leasing, Pharma, Life Sciences

In the league tables

Similar deals

All specialty finance and leasing deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.